A study found that recent increases in Medicare spending on outpatient cancer care at the end of patients’ lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
Zachary SteinhartMaxwell FoiseyDebolina GangulySean Yamada-HunterThe Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees.
